JP4425554B2 - Topical skin preparation - Google Patents
Topical skin preparation Download PDFInfo
- Publication number
- JP4425554B2 JP4425554B2 JP2003076015A JP2003076015A JP4425554B2 JP 4425554 B2 JP4425554 B2 JP 4425554B2 JP 2003076015 A JP2003076015 A JP 2003076015A JP 2003076015 A JP2003076015 A JP 2003076015A JP 4425554 B2 JP4425554 B2 JP 4425554B2
- Authority
- JP
- Japan
- Prior art keywords
- skin
- calcium chloride
- magnesium chloride
- potassium alum
- improving
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002360 preparation method Methods 0.000 title claims description 11
- 230000000699 topical effect Effects 0.000 title 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 50
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 25
- 239000001110 calcium chloride Substances 0.000 claims description 25
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 25
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 25
- 235000011126 aluminium potassium sulphate Nutrition 0.000 claims description 23
- 229940050271 potassium alum Drugs 0.000 claims description 23
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 claims description 23
- 210000003491 skin Anatomy 0.000 claims description 18
- 206010013786 Dry skin Diseases 0.000 claims description 15
- 210000000434 stratum corneum Anatomy 0.000 claims description 13
- 230000004888 barrier function Effects 0.000 claims description 12
- 230000000694 effects Effects 0.000 description 19
- 239000000203 mixture Substances 0.000 description 17
- 238000012360 testing method Methods 0.000 description 11
- 238000009472 formulation Methods 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 239000008346 aqueous phase Substances 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 102000011782 Keratins Human genes 0.000 description 7
- 108010076876 Keratins Proteins 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000006071 cream Substances 0.000 description 6
- -1 pH adjusters Substances 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000003205 fragrance Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000005728 strengthening Methods 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000003788 bath preparation Substances 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- ADEORFBTPGKHRP-UHFFFAOYSA-N 1-[7-(dimethylamino)-4-methyl-2-oxochromen-3-yl]pyrrole-2,5-dione Chemical compound O=C1OC2=CC(N(C)C)=CC=C2C(C)=C1N1C(=O)C=CC1=O ADEORFBTPGKHRP-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
【0001】
【発明が属する分野】
本発明は、優れた肌あれ改善作用を有する皮膚外用剤に関する。
【0002】
【従来の技術】
肌あれの原因として、角質層におけるバリア機能の悪化が考えられており、角質層におけるバリア機能の回復が肌あれ改善皮膚外用剤開発のテーマのひとつとなってきた。
角質層におけるバリア機能はケラチンのSS結合により、保持されている。したがって、この結合が乱れ、遊離のSH基が増加することが、角質層におけるバリア機能悪化の指標と一般的に言われている(非特許文献1参照)。そこで、SS結合を強化する種々の成分が肌あれを改善する皮膚外用剤として開発されている。
肌あれを改善する効果がある成分としては、特許文献1及び非特許文献2に示すカルシウム塩、マグネシウム塩及びカリウム塩が知られている。一方、ミョウバンも非特許文献3に示すように肌あれ改善効果が知られている。
【0003】
【特許文献1】
特開平2001−226248号
【非特許文献1】
清寺眞,「皮膚の生化学」,金原出版株式会社,1966,68−71
【非特許文献2】
Mitsuhiro Denda.,Arch Dermatol Res.,1999,89,560−563
【非特許文献3】
植田理彦,「温泉はなぜ体によいか」,講談社株式会社,1991,39
【0004】
【発明が解決しようとする課題】
角質層におけるバリア機能の悪化に関する指標には種々のものがあり、それらのひとつひとつに対してその作用あるいは抑制する成分を開発することは効率的ではない。角質層におけるバリアはケラチンのSS結合により保持されていることから、ケラチンのSS結合を強化することが、角質層におけるバリア機能を回復し、優れた肌あれ改善効果につながると考えられる。
【0005】
【課題を解決するための手段】
この様な事情により、本発明者らは鋭意研究を重ねた結果、塩化カルシウム、塩化マグネシウムにカリウムミョウバンを加えることにより、さらにケラチンのSS結合を強化し、角質層におけるバリア機能を回復する効果を持つことを見出し、本発明を完成するに至った。
【0006】
すなわち、本発明は、カリウムミョウバン、塩化カルシウム、塩化マグネシウムを含有することを特徴とする肌あれ改善皮膚外用剤である。
【0007】
本発明の肌あれ改善皮膚外用剤には、上記化合物及び/又は植物抽出物をそのまま使用しても良く、効果を損なわない範囲内で、通常の外用剤に用いられる成分である油脂類、ロウ類、炭化水素類、脂肪酸類、アルコール類、エステル類、界面活性剤、金属石鹸、pH調整剤、キレート剤等の成分を配合することもできる。
【0008】
本発明に用いる塩化カルシウム、塩化マグネシウム及びカリウムミョウバンの配合量の総和は0.0001〜10重量%が良い。0.0001%未満では十分な効果は発揮され難い。10重量%を超えて配合した場合、効果の増強は少なく不経済である。また、添加の方法については、予め加えておいても、製造途中で添加しても良く、作業性を考えて適宜選択すれば良い。
【0009】
カリウムミョウバン、塩化カルシウム及び塩化マグネシウムの配合重量比は、塩化カルシウム及び塩化マグネシウムの総和に対して、カリウムミョウバンの0.1〜1000倍を用いるのが良い。中でも、1〜10倍がより好ましい。これ以上のカリウムミョウバンを加えても効果の増強は少なく不経済である。また、塩化カルシウムと塩化マグネシウムの配合比は10:1〜1:10が好ましい。
【0010】
次に本発明を詳細に説明するため、実施例として本発明に用いる塩化カルシウム、塩化マグネシウム、カリウムミョウバンの処方例、実験例を挙げるが、本発明はこれに限定されるものではない。実施例に示す配合量は重量%を示す。
【0011】
実施例1 クリーム
処方 配合量(重量%)
1.塩化カルシウム 0.005
2.塩化マグネシウム 0.005
3.カリウムミョウバン 0.05
4.スクワラン 5.5
5.オリーブ油 3.0
6.ステアリン酸 2.0
7.ミツロウ 2.0
8.ミリスチン酸オクチルドデシル 3.5
9.ポリオキシエチレンセチルエーテル(20E.O.)3.0
10.ベヘニルアルコール 1.5
11.モノステアリン酸グリセリン 2.5
12.香料 0.1
13.1,3−ブチレングリコール 8.5
14.パラオキシ安息香酸エチル 0.05
15.パラオキシ安息香酸メチル 0.2
16.精製水 68.09
「製造方法」成分4〜11を加熱して混合し、70℃に保ち油相とする。成分1〜3及び13〜16を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、45℃で成分12を加え、更に30℃まで冷却して製品とする。
【0012】
比較例1 従来のクリーム
実施例1において、カリウムミョウバンを精製水に置き換えたものを従来のクリームとした。
【0013】
実施例2 化粧水
処方 配合量(重量%)
1.塩化カルシウム 0.001
2.塩化マグネシウム 0.002
3.カリウムミョウバン 0.02
4.1,3−ブチレングリコール 8.0
5.グリセリン 2.0
6.キサンタンガム 0.02
7.クエン酸 0.01
8.クエン酸ナトリウム 0.1
9.エタノール 5.0
10.パラオキシ安息香酸メチル 0.1
11.ポリオキシエチレン硬化ヒマシ油(40E.O.) 0.1
12.香料 0.1
13.精製水 84.547
[製造方法] 成分1〜8及び13と、成分9〜12をそれぞれ均一に溶解し、両者を混合し濾過して製品とする。
【0014】
実施例3 乳液
処方 配合量(重量%)
1.塩化カルシウム 0.001
2.塩化マグネシウム 0.005
3.カリウムミョウバン 0.001
4.スクワラン 5.0
5.オリーブ油 5.0
6.ホホバ油 5.0
7.セタノール 1.5
8.モノステアリン酸グリセリン 2.0
9.ポリオキシエチレンセチルエーテル(20E.O.)3.0
10.ポリオキシエチレンソルビタンモノオレエート 2.0
11.香料 0.1
12.プロピレングリコール 1.0
13.グリセリン 2.0
14.パラオキシ安息香酸メチル 0.2
15.精製水 73.193
[製造方法] 成分4〜10を加熱溶解して混合し、70℃に保ち油相とする。成分1〜3及び12〜15を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、45℃で成分11を加え、更に30℃まで冷却して製品とする。
【0015】
実施例4 軟膏
処方 配合量(重量%)
1.塩化カルシウム 0.002
2.塩化マグネシウム 0.002
3.カリウムミョウバン 0.002
4.ポリオキシエチレンセチルエーテル(30E.O.)2.0
5.モノステアリン酸グリセリン 10.0
6.流動パラフィン 5.0
7.セタノール 6.0
8.パラオキシ安息香酸メチル 0.1
9.プロピレングリコール 10.0
10.精製水 66.894
[製造方法] 成分4〜7を加熱溶解して混合し、70℃に保ち油相とする。成分1〜3及び8〜10を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら30℃まで冷却して製品とする。
【0016】
実施例5 ファンデーション
処方 配合量(重量%)
1.塩化カルシウム 0.005
2.塩化マグネシウム 0.001
3.カリウムミョウバン 0.01
4.ステアリン酸 2.4
5.ポリオキシエチレンソルビタンモノステアレート 1.0
(20E.O.)
6.ポリオキシエチレンセチルエーテル(20E.O.)2.0
7.セタノール 1.0
8.液状ラノリン 2.0
9.流動パラフィン 3.0
10.ミリスチン酸イソプロピル 6.5
11.パラオキシ安息香酸ブチル 0.1
12.カルボキシメチルセルロースナトリウム 0.1
13.ベントナイト 0.5
14.プロピレングリコール 4.0
15.トリエタノールアミン 1.1
16.パラオキシ安息香酸メチル 0.2
17.二酸化チタン 8.0
18.タルク 4.0
19.ベンガラ 1.0
20.黄酸化鉄 2.0
21.香料 0.1
22.精製水 60.984
[製造方法] 成分4〜11を加熱溶解し、80℃に保ち油相とする。成分22に成分12をよく膨張させ、続いて、成分1〜3及び13〜15を加えて均一に混合する。これに粉砕機で粉砕混合した成分17〜19を加え、ホモミキサーで撹拌し75℃に保ち水相とする。この水相に油相をかき混ぜながら加-え、冷却し、45℃で成分21を加え、かき混ぜながら30℃まで冷却して製品とする。
【0017】
実施例6 浴用剤
処方 配合量(重量%)
1.塩化カルシウム 0.001
2.塩化マグネシウム 0.002
3.カリウムミョウバン 0.01
4.炭酸水素ナトリウム 50.0
5.黄色202号(1) 0.05
6.香料 0.25
7.無水硫酸ナトリウム 49.687
[製造方法] 成分1〜7を均一に混合し製品とする。
【0018】
次に、本発明の効果を詳細に説明するため、実験例を挙げる。
【0019】
実験例1 ケラチンのSS結合強化試験
3次元培養皮膚を用い、ケラチンのSS結合強化効果を下記の条件にて測定した。これらの試験は、文献(小島肇夫ら,Tiss CultRes Commun,2001,20(2)110、小川 秀興,日皮会誌,1978,88(8),525−527)を参考にした。
【0020】
3次元培養皮膚(グンゼ株式会社)に被験物質を適用後、約一週間培養した。処理終了後、試料の細胞毒性を評価するため、MTT(3−[4,5−dimethylthiazol−2−yl]―2,5−diphenyl−tetrazolium bromide:Sigma社)0.5mg/mLを含むキット培養液にて2時間処理し、培養片を直径6mmのパンチを用いてくり貫いた後、イソプロパノール(Sigma社)にて還元されたMTT色素を抽出した。この抽出液のOD540をマイクロプレートリーダー(Molecular Device社)にて測定し、溶媒の吸光度を100%とした場合の吸光度を細胞生存率として算出した。70%以上毒性を示さない組織片を試験に供した。なお、未適用の3次元培養皮膚をコントロールとした。
上記処理した3次元培養皮膚を10%ホルマリンにて固定し、パラフィン包埋後、各被験物質の標本を作成した。脱パラフィン後、DACM(N−[7−dimetylamino−4−metyl−3−coumarinyl]maleimid)染色液にてSH基を特異的に染色した。顕微鏡下にて画像処理することにより、角質層蛍光発色面積率を算出し、未適用のコントロールと比較した。
【0021】
これらの試験結果を表1に示した。その結果、塩化カルシウム、塩化マグネシウム及びカリウムミョウバン処理においてSS結合強化効果を認めた。塩化カルシウム及び塩化マグネシウムには角質層バリア機能改善効果があるといわれているが、10mMによる効果であった。それに比べ、カリウムミョウバンは0.1mMとより低濃度で効果を示したことから、試験に用いたミネラルの中で最も角質層バリア機能改善効果が高いと考えられた。
さらに、ミネラルの複合効果について検討した。その結果、塩化カルシウム及び塩化マグネシウム各10mM混合物処理でSS結合強化効果を認めた。ただ、この作用は塩化カルシウム単独処理より弱く、塩化マグネシウムと同等であり、相加的でもないと考えた。塩化カルシウム及び塩化マグネシウム混合物に、さらにカリウムミョウバンを加えると、この作用は相乗的に強くなった。塩化カルシウム及び塩化マグネシウム混合物の濃度が0.01mMと、この濃度ではまったく改善効果がないにも係わらず、効果を示したことから、カリウムミョウバンに塩化カルシウム及び塩化マグネシウム混合物を加えることにより、角質バリア機能の改善に有効であると考えた。
【0022】
【表1】
【0023】
実験例2 使用試験
実施例1のクリーム及び比較例1の従来のクリームを用いて、肌あれに悩む女性各30人(20〜50才)を対象に1ヶ月間の使用試験を行った。使用後、肌あれ改善についてのアンケート調査を行って、肌あれ改善効果を判定した。アンケートの評価基準は、有効なものを「優」、やや有効なものを「良」、わずかに有効なものを「可」、無効なものを「不可」として評価した。
【0024】
これらの結果を表2に示した。実施例1のクリームは優れた肌あれ改善効果を示した。なお、試験期間中皮膚トラブルは一人もなく、安全性においても問題なかった。
【0025】
【表2】
【0026】
実施例2の化粧水、実施例3の乳液、実施例4の軟膏、実施例5のファンデーション及び実施例6の浴用剤の使用試験を実験例と同様に行ったところ、いずれも安全で優れた肌あれ改善効果を示した。
【0027】
以上のことから、本発明の塩化カルシウム及び塩化マグネシウムにカリウムミョウバンを加えることにより、ケラチンのSS結合強化効果を示し、角質層バリア機能改善効果を認めた。塩化カルシウム、塩化マグネシウム及びカリウムミョウバンを含有することを特徴とする肌あれ改善皮膚外用剤は安全で優れた皮膚の肌あれ改善作用を示した。[0001]
[Field of Invention]
The present invention relates to a skin external preparation having an excellent skin roughness improving action.
[0002]
[Prior art]
As a cause of skin roughness, deterioration of the barrier function in the stratum corneum is considered, and restoration of the barrier function in the stratum corneum has been one of the themes of the development of an external preparation for improving skin roughness.
The barrier function in the stratum corneum is retained by keratin SS bonds. Therefore, it is generally said that this bond is disturbed and free SH groups are increased as an indicator of deterioration of the barrier function in the stratum corneum (see Non-Patent Document 1). Accordingly, various components that enhance SS bonding have been developed as an external preparation for skin that improves skin roughness.
As components having an effect of improving skin roughness, calcium salts, magnesium salts and potassium salts shown in Patent Document 1 and Non-Patent Document 2 are known. On the other hand, as shown in Non-Patent Document 3, alum is also known to have a rough skin improving effect.
[0003]
[Patent Document 1]
Japanese Patent Laid-Open No. 2001-226248 [Non-Patent Document 1]
Akira Kiyoji, “Skin Biochemistry”, Kanehara Publishing Co., 1966, 68-71
[Non-Patent Document 2]
Mitshiro Hiro Denda. , Arch Dermatol Res. 1999, 89, 560-563.
[Non-Patent Document 3]
Ueda, Norihiko, “Why hot springs are good for the body”, Kodansha Co., Ltd., 1991, 39
[0004]
[Problems to be solved by the invention]
There are various indicators concerning the deterioration of the barrier function in the stratum corneum, and it is not efficient to develop a component that acts or suppresses each of them. Since the barrier in the stratum corneum is retained by the SS bond of keratin, it is considered that strengthening the SS bond of keratin restores the barrier function in the stratum corneum and leads to an excellent skin roughness improving effect.
[0005]
[Means for Solving the Problems]
Under these circumstances, the present inventors have conducted intensive research. As a result, the addition of potassium alum to calcium chloride and magnesium chloride further strengthens the SS bond of keratin and restores the barrier function in the stratum corneum. As a result, the present invention has been completed.
[0006]
That is, the present invention is a skin external preparation for improving skin roughness characterized by containing potassium alum, calcium chloride, and magnesium chloride .
[0007]
The above-mentioned compounds and / or plant extracts may be used as they are in the skin external preparation for improving skin roughness of the present invention, and the fats and waxes that are components used in ordinary external preparations within the range not impairing the effects. Ingredients, hydrocarbons, fatty acids, alcohols, esters, surfactants, metal soaps, pH adjusters, chelating agents, and the like can also be blended.
[0008]
The total amount of calcium chloride, magnesium chloride and potassium alum used in the present invention is preferably 0.0001 to 10% by weight. If it is less than 0.0001%, a sufficient effect is hardly exhibited. When the blending amount exceeds 10% by weight, the effect is hardly increased and it is uneconomical. In addition, the addition method may be added in advance or during the production, and may be appropriately selected in consideration of workability.
[0009]
The blending weight ratio of potassium alum, calcium chloride and magnesium chloride is preferably 0.1 to 1000 times that of potassium alum relative to the total of calcium chloride and magnesium chloride . Among these, 1 to 10 times is more preferable. Adding more potassium alum is less economical and less expensive. The blending ratio of calcium chloride and magnesium chloride is preferably 10: 1 to 1:10.
[0010]
Next, in order to explain the present invention in detail, formulation examples and experimental examples of calcium chloride, magnesium chloride, and potassium alum used in the present invention are given as examples, but the present invention is not limited thereto. The compounding amount shown in the examples indicates% by weight.
[0011]
Example 1 Cream formulation Formulation amount (% by weight)
1. Calcium chloride 0.005
2. Magnesium chloride 0.005
3. Potassium alum 0.05
4). Squalane 5.5
5). Olive oil 3.0
6). Stearic acid 2.0
7). Beeswax 2.0
8). Octyldodecyl myristate 3.5
9. Polyoxyethylene cetyl ether (20E.O.) 3.0
10. Behenyl alcohol 1.5
11. Glycerol monostearate2.5
12 Fragrance 0.1
13.1,3-Butylene glycol 8.5
14 Ethyl paraoxybenzoate 0.05
15. Methyl paraoxybenzoate 0.2
16. Purified water 68.09
“Manufacturing method” Components 4 to 11 are heated and mixed, and kept at 70 ° C. to obtain an oil phase. Ingredients 1 to 3 and 13 to 16 are dissolved by heating and mixed, and kept at 75 ° C. to obtain an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the mixture is cooled while stirring.
[0012]
Comparative Example 1 Conventional Cream In Example 1, a conventional cream was obtained by replacing potassium alum with purified water.
[0013]
Example 2 skin lotion formulation amount (% by weight)
1. Calcium chloride 0.001
2. Magnesium chloride 0.002
3. Potassium alum 0.02
4.1,3-Butylene glycol 8.0
5). Glycerin 2.0
6). Xanthan gum 0.02
7). Citric acid 0.01
8). Sodium citrate 0.1
9. Ethanol 5.0
10. Methyl paraoxybenzoate 0.1
11. Polyoxyethylene hydrogenated castor oil (40E.O.) 0.1
12 Fragrance 0.1
13. Purified water 84.547
[Manufacturing method] Components 1 to 8 and 13 and components 9 to 12 are uniformly dissolved, and both are mixed and filtered to obtain a product.
[0014]
Example 3 Emulsion Formulation Formulation Amount (% by weight)
1. Calcium chloride 0.001
2. Magnesium chloride 0.005
3. Potassium alum 0.001
4). Squalane 5.0
5). Olive oil 5.0
6). Jojoba oil 5.0
7). Cetanol 1.5
8). Glycerol monostearate 2.0
9. Polyoxyethylene cetyl ether (20E.O.) 3.0
10. Polyoxyethylene sorbitan monooleate 2.0
11. Fragrance 0.1
12 Propylene glycol 1.0
13. Glycerin 2.0
14 Methyl paraoxybenzoate 0.2
15. Purified water 73.193
[Manufacturing method] Components 4 to 10 are heated and dissolved, mixed, and kept at 70 ° C to obtain an oil phase. Ingredients 1 to 3 and 12 to 15 are dissolved by heating and mixed, and kept at 75 ° C. to obtain an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the mixture is cooled while stirring. The component 11 is added at 45 ° C., and further cooled to 30 ° C. to obtain a product.
[0015]
Example 4 Ointment Formulation Amount (% by weight)
1. Calcium chloride 0.002
2. Magnesium chloride 0.002
3. Potassium alum 0.002
4). Polyoxyethylene cetyl ether (30E.O.) 2.0
5). Glycerol monostearate 10.0
6). Liquid paraffin 5.0
7). Cetanol 6.0
8). Methyl paraoxybenzoate 0.1
9. Propylene glycol 10.0
10. Purified water 66.894
[Manufacturing method] Ingredients 4 to 7 are dissolved by heating and mixed, and kept at 70 ° C to obtain an oil phase. Ingredients 1 to 3 and 8 to 10 are dissolved by heating and mixed, and kept at 75 ° C. to obtain an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the mixture is cooled to 30 ° C. with stirring to obtain a product.
[0016]
Example 5 Foundation Formulation Amount (% by weight)
1. Calcium chloride 0.005
2. Magnesium chloride 0.001
3. Potassium alum 0.01
4). Stearic acid 2.4
5). Polyoxyethylene sorbitan monostearate 1.0
(20 EO)
6). Polyoxyethylene cetyl ether (20E.O.) 2.0
7). Cetanol 1.0
8). Liquid lanolin 2.0
9. Liquid paraffin 3.0
10. Isopropyl myristate 6.5
11. Butyl paraoxybenzoate 0.1
12 Sodium carboxymethylcellulose 0.1
13. Bentonite 0.5
14 Propylene glycol 4.0
15. Triethanolamine 1.1
16. Methyl paraoxybenzoate 0.2
17. Titanium dioxide 8.0
18. Talc 4.0
19. Bengala 1.0
20. Yellow iron oxide 2.0
21. Fragrance 0.1
22. Purified water 60.984
[Production Method] Ingredients 4 to 11 are dissolved by heating and kept at 80 ° C. to obtain an oil phase. Ingredient 12 is well swelled into ingredient 22, then ingredients 1-3 and 13-15 are added and mixed uniformly. To this, components 17 to 19 pulverized and mixed with a pulverizer are added, and the mixture is stirred with a homomixer and kept at 75 ° C. to obtain an aqueous phase. Add the oil phase to this aqueous phase while stirring, cool, add component 21 at 45 ° C and cool to 30 ° C with stirring to give the product.
[0017]
Example 6 Bath preparation formulation Formulation amount (% by weight)
1. Calcium chloride 0.001
2. Magnesium chloride 0.002
3. Potassium alum 0.01
4). Sodium bicarbonate 50.0
5). Yellow No. 202 (1) 0.05
6). Fragrance 0.25
7). Anhydrous sodium sulfate 49.687
[Production Method] Components 1 to 7 are uniformly mixed to obtain a product.
[0018]
Next, experimental examples will be given to explain the effects of the present invention in detail.
[0019]
Experimental Example 1 SS Bond Strengthening Test of Keratin Using a three-dimensional cultured skin, the SS bond strengthening effect of keratin was measured under the following conditions. These tests were based on literature (Tatsuo Kojima et al., Tis CultRes Commun, 2001, 20 (2) 110, Hideki Ogawa, Journal of the Japanese Society of Skin, 1978, 88 (8), 525-527).
[0020]
After applying the test substance to the three-dimensional cultured skin (Gunze Co., Ltd.), it was cultured for about one week. After the treatment, kit culture containing 0.5 mg / mL of MTT (3- [4,5-dimethylthiazol-2-yl] -2,5-diphenyl-tetrazolium bromide: Sigma) to evaluate the cytotoxicity of the sample After treatment with the solution for 2 hours, the culture piece was punched using a punch with a diameter of 6 mm, and the MTT dye reduced with isopropanol (Sigma) was extracted. The OD 540 of this extract was measured with a microplate reader (Molecular Device), and the absorbance when the absorbance of the solvent was 100% was calculated as the cell viability. Tissue pieces that did not show more than 70% toxicity were subjected to the test. A non-applied three-dimensional cultured skin was used as a control.
The treated three-dimensional cultured skin was fixed with 10% formalin, embedded in paraffin, and a specimen of each test substance was prepared. After deparaffinization, the SH group was specifically stained with DACM (N- [7-dimethylamino-4-methyl-3-coumarinyl] maleimid) staining solution. By image processing under a microscope, the stratum corneum fluorescence color development area ratio was calculated and compared with an unapplied control.
[0021]
The test results are shown in Table 1. As a result, the SS bond strengthening effect was recognized in calcium chloride, magnesium chloride and potassium alum treatment. Calcium chloride and magnesium chloride are said to have an effect of improving the stratum corneum barrier function, but the effect was due to 10 mM. In contrast, potassium alum showed an effect at a lower concentration of 0.1 mM, and therefore, it was considered that the effect of improving the stratum corneum barrier function was the highest among the minerals used in the test.
Furthermore, the combined effect of minerals was examined. As a result, the SS bond strengthening effect was recognized by treatment with 10 mM each of calcium chloride and magnesium chloride. However, this action was weaker than that of calcium chloride alone, equivalent to magnesium chloride, and not considered additive. This action was synergistically enhanced when additional potassium alum was added to the calcium chloride and magnesium chloride mixture. The concentration of the calcium chloride and magnesium chloride mixture was 0.01 mM, and this concentration showed no effect at all. However, by adding the calcium chloride and magnesium chloride mixture to potassium alum, We thought it was effective in improving the function.
[0022]
[Table 1]
[0023]
Experimental Example 2 Use Test Using the cream of Example 1 and the conventional cream of Comparative Example 1, a use test was conducted for one month for 30 women (20 to 50 years old) who suffer from rough skin. After use, a questionnaire survey on skin roughness improvement was conducted to determine the effect of skin roughness improvement. The evaluation criteria of the questionnaire were evaluated as “excellent” for valid, “good” for slightly effective, “good” for slightly effective, and “impossible” for invalid.
[0024]
These results are shown in Table 2. The cream of Example 1 showed an excellent improvement effect on skin roughness. During the test period, there was no skin problem and there was no problem with safety.
[0025]
[Table 2]
[0026]
A test for the use of the lotion of Example 2, the emulsion of Example 3, the ointment of Example 4, the foundation of Example 5 and the bath preparation of Example 6 was carried out in the same manner as in the experimental examples, all of which were safe and excellent. It showed an improvement effect on the skin.
[0027]
From the above, by adding potassium alum to the calcium chloride and magnesium chloride of the present invention, the effect of enhancing the keratin SS bond was shown, and the effect of improving the stratum corneum barrier function was recognized. The skin external preparation for improving skin roughness, characterized by containing calcium chloride, magnesium chloride and potassium alum , showed a safe and excellent skin roughness improving action.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003076015A JP4425554B2 (en) | 2003-03-19 | 2003-03-19 | Topical skin preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003076015A JP4425554B2 (en) | 2003-03-19 | 2003-03-19 | Topical skin preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004284962A JP2004284962A (en) | 2004-10-14 |
| JP4425554B2 true JP4425554B2 (en) | 2010-03-03 |
Family
ID=33291174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003076015A Expired - Lifetime JP4425554B2 (en) | 2003-03-19 | 2003-03-19 | Topical skin preparation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4425554B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2021215440A1 (en) * | 2020-04-22 | 2021-10-28 |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007013623A (en) | 2005-04-28 | 2008-02-12 | Cosmo Oil Co Ltd | External preparation for skin. |
| CA2612674C (en) * | 2005-06-20 | 2013-06-25 | Playtex Products, Inc. | Non-irritating cosmetic or dermatological compositions |
| KR100863617B1 (en) * | 2007-04-19 | 2008-10-15 | 바이오스펙트럼 주식회사 | Skin condition improvement composition comprising alum as an active ingredient |
| WO2009038444A1 (en) * | 2007-09-19 | 2009-03-26 | Adil Hssine | Organic anti-wrinkle cream |
| GB2516409A (en) * | 2012-04-19 | 2015-01-28 | Wisam Fouad Al-Badri | Babylon gel |
| JP7239163B2 (en) * | 2019-03-08 | 2023-03-14 | 株式会社ダリヤ | Cosmetics for wiping off |
| JP7253944B2 (en) * | 2019-03-19 | 2023-04-07 | 株式会社マンダム | cosmetic composition |
-
2003
- 2003-03-19 JP JP2003076015A patent/JP4425554B2/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2021215440A1 (en) * | 2020-04-22 | 2021-10-28 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004284962A (en) | 2004-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2565513B2 (en) | Topical drug for suppressing melanin production | |
| JP3135943B2 (en) | Whitening agent | |
| WO2007148832A1 (en) | Skin whitening agent containing zinc as active ingredient | |
| JP2890212B2 (en) | Cosmetics | |
| JP2012514004A5 (en) | ||
| JP4425554B2 (en) | Topical skin preparation | |
| JPH0725742A (en) | Whitening cosmetics | |
| JP2009029734A (en) | External preparation for skin | |
| JPH11255639A (en) | Tyrosinase activity inhibitor and cosmetic | |
| JPH10101543A (en) | Tyrosinase-activity inhibitor, and cosmetic | |
| JP5669436B2 (en) | Composition | |
| JP2004161641A (en) | Cosmetic | |
| JP2011241164A5 (en) | ||
| JP5184813B2 (en) | Collagen production promotion and degradation inhibitor | |
| JP2003176217A (en) | Skin care preparation | |
| JP2002326942A (en) | Preparation for external use for skin | |
| JPH1072330A (en) | Tyrosinase activity inhibitor and cosmetic | |
| JP5552741B2 (en) | Whitening agent containing zinc as an active ingredient | |
| JP3010560B2 (en) | Cosmetics | |
| JP3027409B2 (en) | Cosmetics | |
| JP2753639B2 (en) | Cosmetics | |
| JP3023543B2 (en) | Tyrosinase activity inhibitor and cosmetic | |
| JP3452671B2 (en) | External preparation for skin | |
| JP2002234828A (en) | Skin whitening cosmetic preparation | |
| JP2003171256A (en) | Skin care preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20041117 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060120 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090721 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090918 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20091208 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20091209 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121218 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131218 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |